Search

everythinglearnresearchcommunity

for

Search:↓

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

Upadacitinib effectively treats psoriasis and lichen planus together.

Entospletinib effectively prevents eye and skin GVHD in mice.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tofacitinib may help regrow hair in alopecia areata patients.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

JAK inhibitors may help improve symptoms in adults with APECED.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.